Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

gynecomastia in patients with dasatinib and imatin

More
10 years 1 month ago #741 by guadalupe
I wiil ask about frecuency and management the patients with gynecomastia with Imatinib or Dasatinib
  • Michele Baccarani
  • Michele Baccarani's Avatar
9 years 11 months ago #800 by Michele Baccarani
Replied by Michele Baccarani on topic Re: gynecomastia in patients with dasatinib and imatin
It is impossible to establish the frequency of gynecomastia during TKIs treatment, but since there are no reports (as far as I remember, but Dr. Perez can do a medline) I presume that gynecomastia is a very rare adverse event. Please remember that since the average patient with CML is male and has a median age of 55 to 60 years, some patients will develop gynecomastia irrespective of treatment.
Having said that, it may be relevant to remember that there are few, unconfirmed reports, of a decrease of testosterone and of fertility in male patients. But again, the frequency (unknown) should be compared with the frequency of the same findings in a control population. There are several reports of a “second” malignancy in CML patients treated by TKI, but breast cancer incidence was not recorded.
From a practical point of view, in case of clinically significant gynecomastia, a study of the appropriate hormones and an ultrasound examination of breast are advised. If the patient is in stable deep molecular response it may be possible to discontinue treatment for few weeks with careful molecular monitoring, to see if treatment discontinuation has any effect on gynecomastia. But only in case of very stable and very deep response, because in these cases we know that if after discontinuation there is a molecular relapse, the molecular response will be achieved again upon retreatment. In any other case, the TKI should not be discontinued.
  • Jeff Lipton
  • Jeff Lipton's Avatar
9 years 11 months ago #801 by Jeff Lipton
Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P,
Pecori-Giraldi F, Mariani L, et al. Gynaecomastia in men
with chronic myeloid leukaemia after imatinib. Lancet 2003;
361:1954 – 1956.

As Dr Baccarani reported, there were reports from a number of years ago about this phenomenon. Subsequently we reported a case of unusual fluid retention in breast tissue in women (Ostro D, Lipton JH (2007) Unusual Fluid Retention with Imatinib Therapy for Chronic Myeloid Leukemia. Leuk Lymph 48: 195-6)

I think the first case series above looks at a number of endocrinologic aspects of the work up that should be considered. It is however necessary to distinguish between legitimate gynecomastia and unusal manifestations of fluid retention.

If it turns out to be imatinib related, then the only therapy if disconcerting enough, but be a switch in medications. In the case of the fluid retention, we did not find that aggressive diuretic therapy was effective. In fact the patient in question, went on to cosmetic breast reduction therapy, and then recurred as would be expected, post surgery, a phenomenon that has been reported with blepheroplasty under similar circumstances.
Moderators: Nicolaarlene